tiprankstipranks
Trending News
More News >
Dyne Therapeutics (DYN)
NASDAQ:DYN
US Market
Advertisement

Dyne Therapeutics (DYN) AI Stock Analysis

Compare
379 Followers

Top Page

DYN

Dyne Therapeutics

(NASDAQ:DYN)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 4o)
Rating:43Neutral
Price Target:
Dyne Therapeutics' stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.
Positive Factors
Strong Balance Sheet
A strong balance sheet with significant cash reserves and low debt levels provides Dyne Therapeutics with the financial stability needed to sustain its R&D activities and weather the challenges of being a pre-revenue biotech firm.
Strategic Leadership Change
The appointment of Erick Lucera as CFO, with his extensive biotech financial leadership experience, is expected to enhance Dyne's financial strategy and operational efficiency, potentially improving its market positioning and long-term growth prospects.
Proprietary FORCE Platform
Dyne's proprietary FORCE platform for delivering nucleic acid therapeutics to muscle tissue positions it uniquely in the biotech industry, offering a competitive advantage in developing treatments for rare muscle disorders.
Negative Factors
Zero Revenue
Consistently reporting zero revenue highlights Dyne's early-stage status and reliance on future product commercialization, which poses a risk to financial sustainability if product development does not progress as planned.
Increasing Net Losses
Increasing net losses reflect high operational expenses without offsetting revenue streams, challenging Dyne's financial health and necessitating successful product development and commercialization to achieve profitability.
Negative Cash Flow
Deeply negative cash flows due to heavy R&D investments highlight the financial strain on Dyne, emphasizing the need for successful capital raising and strategic partnerships to sustain operations until revenue generation begins.

Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)

Dyne Therapeutics Business Overview & Revenue Model

Company DescriptionDyne Therapeutics (DYN) is a biotechnology company focused on developing targeted therapies for patients with genetically driven diseases. The company specializes in advancing innovative treatments for rare muscle disorders, leveraging its proprietary FORCE platform to deliver nucleic acid therapeutics precisely to muscle tissue. Dyne's pipeline includes programs aimed at treating conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.
How the Company Makes MoneyDyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary
Dyne Therapeutics exhibits characteristics typical of an early-stage biotech firm: significant cash reserves and low leverage support its R&D focus, despite zero revenue and increasing net losses. The strong balance sheet mitigates the risks associated with negative cash flows, contingent on future breakthroughs and commercialization.
Income Statement
15
Very Negative
Dyne Therapeutics has consistently reported zero revenue over the years, reflecting its early-stage position in the biotechnology sector focused on R&D. The company incurs substantial net losses, which have been increasing over time, indicating high operational expenses without offsetting revenue streams. This results in negative profit margins across all metrics, which is typical for a biotech firm in the pre-commercial phase.
Balance Sheet
70
Positive
The balance sheet is relatively strong with a significant amount of cash and short-term investments, which is crucial for sustaining R&D activities. The company maintains low debt levels relative to its equity, reflected in a healthy debt-to-equity ratio. A robust equity ratio indicates a strong capital structure, providing financial stability and reducing immediate liquidity risks.
Cash Flow
40
Negative
Cash flows are deeply negative, driven by heavy R&D investments, a common scenario for pre-revenue biotech companies. However, the substantial cash on hand and positive financing cash flow from equity funding highlight the company's ability to raise capital, enabling it to continue its development projects despite negative free cash flow growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.57M0.000.000.000.000.00
Gross Profit286.00K-2.24M-2.46M-3.35M-1.09M-700.00K
EBITDA-439.54M-315.18M-233.48M-164.75M-148.20M-58.34M
Net Income-412.88M-317.42M-235.94M-165.24M-149.28M-58.74M
Balance Sheet
Total Assets728.99M691.23M165.08M306.32M425.66M353.33M
Cash, Cash Equivalents and Short-Term Investments683.92M642.27M123.10M256.01M376.57M345.31M
Total Debt22.26M23.99M27.41M30.48M32.64M0.00
Total Liabilities157.55M61.40M73.79M53.96M57.47M10.97M
Stockholders Equity571.45M629.84M91.29M252.36M368.20M342.37M
Cash Flow
Free Cash Flow-361.93M-294.75M-188.89M-156.71M-123.18M-47.67M
Operating Cash Flow-359.56M-292.37M-188.16M-153.65M-119.56M-46.51M
Investing Cash Flow-27.18M-204.08M83.31M87.20M-137.89M-45.66M
Financing Cash Flow263.66M809.89M54.32M37.39M157.82M380.69M

Dyne Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.58
Price Trends
50DMA
11.99
Positive
100DMA
11.61
Positive
200DMA
13.25
Negative
Market Momentum
MACD
0.22
Positive
RSI
52.90
Neutral
STOCH
29.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Positive. The current price of 12.58 is below the 20-day moving average (MA) of 13.28, above the 50-day MA of 11.99, and below the 200-day MA of 13.25, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 52.90 is Neutral, neither overbought nor oversold. The STOCH value of 29.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYN.

Dyne Therapeutics Risk Analysis

Dyne Therapeutics disclosed 83 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Dyne Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
1.65B-4.73-66.79%5.90%-0.36%
48
Neutral
1.08B-7.62-88.27%-14.98%-51.76%
48
Neutral
1.35B-4.022133.71%-15.38%
46
Neutral
763.51M-1.72-55.82%636.99%27.10%
43
Neutral
$1.87B-61.32%-7.71%
36
Underperform
1.19B-10.00-3.53%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DYN
Dyne Therapeutics
13.15
-20.68
-61.13%
SRPT
Sarepta Therapeutics
18.36
-106.17
-85.26%
COGT
Cogent Biosciences
14.16
3.26
29.91%
ARQT
Arcutis Biotherapeutics
17.57
8.21
87.71%
BEAM
Beam Therapeutics
22.97
-2.08
-8.30%
IMCR
Immunocore Holdings
34.02
2.62
8.34%

Dyne Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Dyne Therapeutics Appoints Erick Lucera as CFO
Positive
Mar 20, 2025

On March 20, 2025, Dyne Therapeutics announced the appointment of Erick Lucera as Chief Financial Officer and Treasurer, effective March 31, 2025. This strategic move follows Lucera’s extensive experience in financial leadership roles within the biotechnology sector, notably at Editas Medicine and AVEO Pharmaceuticals. His appointment coincides with the departure of Richard Scalzo, who will transition to a consulting role. These changes are expected to enhance Dyne Therapeutics’ financial strategy and operational efficiency, potentially impacting its market positioning positively.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025